POLARIX: This phase III trial is comparing the addition of an investigational drug (polatuzumab vedotin) to R-CHP and R-CHOP chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Exclusion

• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
• Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines
• Prior organ transplantation
• Current Grade greater than (>) 1 peripheral neuropathy by clinical examination
• Demyelinating form of Charcot-Marie-Tooth disease
• History of indolent lymphoma
• History of follicular lymphoma grade 3B
• B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (grey-zone lymphoma)
• Primary mediastinal (thymic) large B-cell lymphoma
• Burkitt lymphoma
• Prior treatment with cytotoxic drugs within 5 years of screening for any condition (example [e.g.], cancer, rheumatoid arthritis) or prior use of any anti-CD20 antibody
• Prior use of any monoclonal antibody within 3 months of the start of Cycle 1
• Prior therapy for DLBCL, with the exception of nodal biopsy
• Corticosteroid use >30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control
• Participants with central nervous system (CNS) lymphoma (primary or secondary involvement), primary effusion DLBCL, and primary cutaneous DLBCL
• Vaccination with live vaccines within 28 days prior to the start of Cycle 1
• Any investigational therapy within 28 days prior to the start of Cycle 1
• History of other malignancy that could affect compliance with the protocol or interpretation of results
• Evidence of significant, uncontrolled, concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease
• Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
• History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction
• Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or significant infections within 2 weeks before the start of Cycle 1
• Clinically significant liver disease, including active viral or other hepatitis, current alcohol abuse, or cirrhosis
• Prior radiotherapy to the mediastinal/pericardial region
• Participants with suspected active or latent tuberculosis
• Positive test results for chronic hepatitis B and hepatitis C infection
• Known history of human immunodeficiency virus (HIV) seropositive status
• Positive results for the human T-lymphotrophic 1 virus (HTLV-1)
• Participants with a history of progressive multifocal leukoencephalopathy